{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T03:19:43Z","timestamp":1774408783670,"version":"3.50.1"},"reference-count":16,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["NIHR131306"],"award-info":[{"award-number":["NIHR131306"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,11,16]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Lung cancer is the most common cause of cancer death worldwide and most patients present with extensive disease. One-year survival is improving but remains low (37%) despite novel systemic anti-cancer treatments forming the current standard of care. Although new therapies improve survival, most patients have residual disease after treatment, and little is known on how best to manage it. Therefore, residual disease management varies across the UK, with some patients receiving only maintenance systemic anti-cancer treatment while others receive local consolidative treatment (LCT), alongside maintenance systemic anti-cancer treatment. LCT can be a combination of surgery, radiotherapy and\/or ablation to remove all remaining cancer within the lung and throughout the body. This is intensive, expensive and impacts quality of life, but we do not know if it results in better survival, nor the extent of impact on quality of life and what the cost might be for healthcare providers. The RAMON study (RAdical Management Of Advanced Non-small cell lung cancer) will evaluate the acceptability, effectiveness and cost-effectiveness of LCT versus no LCT after first-line systemic treatment for advanced lung cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>RAMON is a pragmatic open multicentre, parallel group, superiority randomised controlled trial. We aim to recruit 244 patients aged 18 years and over with advanced non-small-cell lung cancer from 40 UK NHS hospitals. Participants will be randomised in a 1:1 ratio to receive LCT alongside maintenance treatment, or maintenance treatment alone. LCT will be tailored to each patient\u2019s specific disease sites. Participants will be followed up for a minimum of 2\u2009years. The primary outcome is overall survival from randomisation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The West of Scotland Research Ethics Committee (22\/WS\/0121) gave ethical approval in August 2022 and the Health Research Authority in September 2022. Participants will provide written informed consent before participating in the study. Findings will be presented at international meetings, in peer-reviewed publications, through patient organisations and notifications to patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN11613852\">ISRCTN11613852<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-081650","type":"journal-article","created":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T11:26:52Z","timestamp":1702207612000},"page":"e081650","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Multimodality local consolidative treatment versus conventional care of advanced lung cancer after first-line systemic anti-cancer treatment: study protocol for the RAMON multicentre randomised controlled trial with an internal pilot"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"isrctn11613852","registry":"10.18810\/isrctn"},{"clinical-trial-number":"nct02417662","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01796288","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02759783","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03721341","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9802-4171","authenticated-orcid":false,"given":"Chloe","family":"Beard","sequence":"first","affiliation":[{"name":"Bristol Trials Centre, University of Bristol Medical School, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-2615","authenticated-orcid":false,"given":"Chris A","family":"Rogers","sequence":"additional","affiliation":[{"name":"Bristol Trials Centre, University of Bristol Medical School, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5070-352X","authenticated-orcid":false,"given":"Leah","family":"Fleming","sequence":"additional","affiliation":[{"name":"Bristol Trials Centre, University of Bristol Medical School, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5096-7074","authenticated-orcid":false,"given":"John","family":"Conibear","sequence":"additional","affiliation":[{"name":"Bart's Cancer Centre, Bart\u2019s Health NHS Trust, St Bartholomew's Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4066-5253","authenticated-orcid":false,"given":"Matthew","family":"Evison","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9317-3434","authenticated-orcid":false,"given":"Thomas","family":"Newsom-Davis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9776-8766","authenticated-orcid":false,"given":"Tara","family":"Barwick","sequence":"additional","affiliation":[{"name":"Department of Radiology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2960-2940","authenticated-orcid":false,"given":"Nicola","family":"Mills","sequence":"additional","affiliation":[{"name":"Population Health Sciences, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4179-1369","authenticated-orcid":false,"given":"Elizabeth A","family":"Stokes","sequence":"additional","affiliation":[{"name":"Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-4116","authenticated-orcid":false,"given":"Paulo","family":"De Sousa","sequence":"additional","affiliation":[{"name":"Cancer Services, Royal Brompton and Harefield NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4103-6061","authenticated-orcid":false,"given":"Tim","family":"Batchelor","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Bart\u2019s Health NHS Trust, St Bartholomew's Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janette","family":"Rawlinson","sequence":"additional","affiliation":[{"name":"Patient and Public Involvement (PPI, Lung Cancer Specialty) based in England, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2039-8768","authenticated-orcid":false,"given":"Sarah","family":"Baos","sequence":"additional","affiliation":[{"name":"Bristol Trials Centre, University of Bristol Medical School, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2405-667X","authenticated-orcid":false,"given":"Rosie","family":"Harris","sequence":"additional","affiliation":[{"name":"Bristol Trials Centre, University of Bristol Medical School, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9078-3226","authenticated-orcid":false,"given":"Eric","family":"Lim","sequence":"additional","affiliation":[{"name":"Academic Division of Thoracic Surgery, Royal Brompton and Harefield Hospitals, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,12,10]]},"reference":[{"key":"2025121408420209000_13.12.e081650.1","unstructured":"Royal College of Physicians . National Lung Cancer Audit annual report 2018 (for the audit period 2017). London: Royal College of Physicians, 2019."},{"key":"2025121408420209000_13.12.e081650.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.07.025"},{"key":"2025121408420209000_13.12.e081650.3","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025121408420209000_13.12.e081650.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32487-5"},{"key":"2025121408420209000_13.12.e081650.5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020690","article-title":"Study protocol for the SARON trial: a Multicentre, randomised controlled phase III trial comparing the addition of stereotactic Ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for Oligometastatic non-small cell lung cancer","volume":"8","author":"Conibear","year":"2018","journal-title":"BMJ Open"},{"key":"2025121408420209000_13.12.e081650.6","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2018.02.061","article-title":"A randomised trial of conventional care versus radioablation (stereotactic body radiotherapy) for Extracranial Oligometastases","volume":"30","author":"Khoo","year":"2018","journal-title":"Clinical Oncology"},{"key":"2025121408420209000_13.12.e081650.7","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5977-6","article-title":"Stereotactic Ablative radiotherapy for the comprehensive treatment of 4\u201310 Oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"},{"key":"2025121408420209000_13.12.e081650.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30718-1"},{"key":"2025121408420209000_13.12.e081650.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00201"},{"key":"2025121408420209000_13.12.e081650.10","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-016-1391-4","article-title":"Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the Quintet recruitment intervention (QRI)","volume":"17","author":"Donovan","year":"2016","journal-title":"Trials"},{"key":"2025121408420209000_13.12.e081650.11","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1177\/1049732319828693","article-title":"Intensive Triangulation of qualitative research and quantitative data to improve recruitment to randomized trials: the Quintet approach","volume":"29","author":"Rooshenas","year":"2019","journal-title":"Qual Health Res"},{"key":"2025121408420209000_13.12.e081650.12","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jclinepi.2018.10.004","article-title":"By-band-sleeve study group; CSAW study group; HAND-1 study group; OPTIMA Prelim study group; Romio feasibility study group. The Quintet recruitment intervention supported five randomized trials to recruit to target: a mixed-methods evaluation","volume":"106","author":"Rooshenas","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"2025121408420209000_13.12.e081650.13","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"2025121408420209000_13.12.e081650.14","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2025121408420209000_13.12.e081650.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2025121408420209000_13.12.e081650.16","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4067"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-081650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:42:07Z","timestamp":1765730527000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-081650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":16,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,10]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/bmjopen-2023-081650"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-081650","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}